Plus Therapeutics Presents RESPECT Phase 1 Metastases Data
Plus Therapeutics will present Phase 1 dose-escalation results of rhenium-186 obisbemeda (ReYobiq), an injectable radiotherapy for leptomeningeal metastases, in...
No videos found.
Kala Bio Enters $6M Securities Purchase Agreement with Lazar
Kala Bio has secured a $6 million financing via non-voting convertible preferred stock from private investor David E. Lazar,...
CEO’s Spotlight on MediciNova’s Profitable Growth Path
MediciNova has completed enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of MN-001 (tipelukast) in patients with hypertriglyceridemia...
Empaveli Phase 3 VALIANT Results Published for C3G, IC-MPGN
Apellis’ pegcetacoplan has crossed a credibility threshold in rare nephrology: Phase 3 VALIANT results for C3 glomerulopathy and primary...
Lamy Completes Acquisition of Cancer Innovator Exousia AI
LAMY, soon to be rebranded as Exousia Bio (OTCPINK: LMMY), has completed an all‑stock acquisition of Exousia AI, issuing...
Lamy’s Strategic Acquisition of Exousia AI in Cancer Tech
Lamy, set to rebrand as Exousia Bio, has acquired 100% of Exousia AI in an all‑stock deal, issuing 62,223,000...
Novabridge Presents Ragistomig Expanded Phase 1 Data
NovaBridge Biosciences will present new data from its expanded phase 1 study of ragistomig (ABL503), a PD-L1 × 4-1BB...
TScan Virtual Event: Alloha™ Phase 1 Updates & Opportunities
TScan Therapeutics will host a virtual KOL event on December 8 to review updated two-year relapse data from its...
Iolyx Inks Dry Eye Deal With Théa, Secures Series B Funds
Iolyx Therapeutics has signed a global development and commercialization deal with Laboratoires Théa for ILyx-002 in ocular surface disease,...
Advancing Medical Operations with Deep KOL Intelligence and AI
At the 2025 Veeva Commercial Summit, we spoke with Eric Toron, Executive Director and Head of Operations at MSD...